Polymer affinity system for the delivery of cytotoxic material and other compounds to sites of disease

• US 5,686,071 A
• Filed: 06/06/1995
• Issued: 11/11/1997
• Est. Priority Date: 06/06/1995
• Status: Expired due to Fees

• Current Assignee: Perimmune Holdings Incorporated
• Original Assignee: Perimmune Holdings Incorporated
• Inventors: Shi, Fang, Subramanian, Ramaswamy
• Primary Examiner(s): Feisee, Lila
• Assistant Examiner(s): Reeves, Julie E.
• Application Number:
  US08/471,264
• Time in Patent Office: 889 Days
• Field of Search: 424/487, 424/280.1, 424/488, 424/179.1, 430/18, 525/54.1, 525/326.9, 525/329.5, 525/329.7, 526/318.3, 530/391.1
• US Class Current: 424/179.1
• CPC Class Codes: A61K 47/68 the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• CPC Class Codes: A61K 47/6897 Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
• CPC Class Codes: A61K 51/1093 conjugates with carriers being antibodies
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The use of interacting polymers and oligomers to selectively target compounds to desired sites, in-vitro and in-vivo, wherein the first polymer or oligomer is bound to a targeting agent and the second polymer or oligomer is bound to an active agent, such as a drug, a metal or a radioisotope.

Claims

1. A method for targeting active agents to target sites, comprising

providing two polymers that have binding affinity for each other,

coupling a targeting agent to the first of the polymers to form a targeting agent-polymer conjugate,

coupling an active agent to the second of the polymers in the pair to form an active agent-polymer complex,

administering the targeting agent-polymer conjugate to a subject,

permitting the conjugate to localize to a target tissue for which the targeting agent has affinity,

administering the active agent-polymer complex to the subject, and

permitting the complex to bind to the localized targeting-agent polymer conjugate, whereby the active agent becomes localized to the target tissue,

wherein the targeting agent is an antibody or an antigen binding fragment having binding specificity for a tumor associated antigen and retaining that specificity in the targeting agent-polymer conjugate, wherein the active agent is selected from the group consisting of a radiometal, a radiohalogen, a metal with magnetic properties and fluorescent metal, and wherein the polymers are selected from the group consisting of poly (N-vinyl pyrrolidone), poly (ethyleneminine) and ply (acrylic acid).

2. The method of claim 1, wherein the subject is a mammal.

3. The method of claim 1, wherein the active agent comprises a chelator.